Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan
· Delayed Price · Currency is JPY 1,434.00
+26.50 (1.88%)
Feb 21, 2025, 3:30 PM JST
Santen Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | 27,471 | 26,703 | -14,983 | 27,189 | 6,645 | 21,714 | Upgrade
|
| Depreciation & Amortization | 18,109 | 18,178 | 17,249 | 17,055 | 16,768 | 16,573 | Upgrade
|
| Loss (Gain) From Sale of Assets | 7,977 | 7,779 | 34,560 | 232 | 40,664 | 5,825 | Upgrade
|
| Loss (Gain) on Equity Investments | 4,645 | 7,575 | 2,362 | 1,604 | 358 | - | Upgrade
|
| Other Operating Activities | -11,362 | -12,287 | -7,990 | -10,318 | -12,916 | -14,150 | Upgrade
|
| Change in Accounts Receivable | 16,894 | 18,384 | -6,443 | -1,965 | -7,514 | -3,054 | Upgrade
|
| Change in Inventory | -1,278 | -1,369 | -1,144 | 5,383 | -4,590 | -981 | Upgrade
|
| Change in Accounts Payable | -13,671 | -2,369 | 1,690 | 2,748 | 8,147 | 2,022 | Upgrade
|
| Change in Other Net Operating Assets | 6,462 | 10,055 | 11,846 | 4,115 | -8,754 | 11,998 | Upgrade
|
| Operating Cash Flow | 55,247 | 72,649 | 37,147 | 46,043 | 38,808 | 39,947 | Upgrade
|
| Operating Cash Flow Growth | -18.88% | 95.57% | -19.32% | 18.64% | -2.85% | 21.44% | Upgrade
|
| Capital Expenditures | -9,046 | -9,319 | -17,277 | -17,344 | -4,139 | -5,824 | Upgrade
|
| Cash Acquisitions | - | -207 | -3,470 | -2,969 | -29,183 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -3,071 | -572 | -7,311 | -18,497 | -19,665 | -3,404 | Upgrade
|
| Investment in Securities | 4,643 | 3,826 | 1,560 | 2,803 | -314 | 3,105 | Upgrade
|
| Other Investing Activities | -189 | 127 | -279 | 838 | -54 | 948 | Upgrade
|
| Investing Cash Flow | -7,663 | -6,145 | -26,777 | -35,169 | -53,355 | -5,175 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 10,460 | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | 15,639 | 10,000 | 307 | 1,477 | Upgrade
|
| Total Debt Issued | - | - | 15,639 | 20,460 | 307 | 1,477 | Upgrade
|
| Short-Term Debt Repaid | - | - | -11,278 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -2,112 | - | - | -3,000 | -500 | Upgrade
|
| Total Debt Repaid | -1,953 | -2,112 | -11,278 | - | -3,000 | -500 | Upgrade
|
| Net Debt Issued (Repaid) | -1,953 | -2,112 | 4,361 | 20,460 | -2,693 | 977 | Upgrade
|
| Repurchase of Common Stock | -37,883 | -16,962 | -26,007 | - | - | -22 | Upgrade
|
| Dividends Paid | -12,133 | -11,881 | -12,607 | -11,994 | -11,188 | -10,379 | Upgrade
|
| Other Financing Activities | -3,188 | -3,076 | -2,967 | -2,909 | -2,804 | -3,305 | Upgrade
|
| Financing Cash Flow | -55,157 | -34,031 | -37,220 | 5,557 | -16,685 | -12,729 | Upgrade
|
| Foreign Exchange Rate Adjustments | 3,394 | 4,206 | 1,739 | 3,694 | 2,690 | -1,410 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | 1 | - | 1 | Upgrade
|
| Net Cash Flow | -4,179 | 36,679 | -25,111 | 20,126 | -28,542 | 20,634 | Upgrade
|
| Free Cash Flow | 46,201 | 63,330 | 19,870 | 28,699 | 34,669 | 34,123 | Upgrade
|
| Free Cash Flow Growth | -22.06% | 218.72% | -30.76% | -17.22% | 1.60% | 24.43% | Upgrade
|
| Free Cash Flow Margin | 15.30% | 20.97% | 7.12% | 10.78% | 13.89% | 14.13% | Upgrade
|
| Free Cash Flow Per Share | 130.04 | 172.03 | 51.29 | 71.67 | 86.59 | 85.25 | Upgrade
|
| Cash Interest Paid | 1,041 | 830 | 465 | 240 | 159 | 190 | Upgrade
|
| Cash Income Tax Paid | 11,272 | 12,108 | 7,818 | 10,246 | 12,834 | 14,149 | Upgrade
|
| Levered Free Cash Flow | 39,658 | 57,849 | 10,007 | 6,630 | 23,856 | 30,667 | Upgrade
|
| Unlevered Free Cash Flow | 40,386 | 58,369 | 10,305 | 6,786 | 23,956 | 30,786 | Upgrade
|
| Change in Net Working Capital | -2,380 | -17,466 | 4,419 | -3,150 | 2,451 | 1,472 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.